Does MOMETASONE Cause Bladder transitional cell carcinoma? 22 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 22 reports of Bladder transitional cell carcinoma have been filed in association with MOMETASONE (MOMETASONE FUROATE). This represents 1.3% of all adverse event reports for MOMETASONE.
22
Reports of Bladder transitional cell carcinoma with MOMETASONE
1.3%
of all MOMETASONE reports
0
Deaths
22
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From MOMETASONE?
Of the 22 reports, 22 (100.0%) required hospitalization.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for MOMETASONE. However, 22 reports have been filed with the FAERS database.
What Other Side Effects Does MOMETASONE Cause?
Asthma (522)
Dyspnoea (497)
Wheezing (459)
Gastrooesophageal reflux disease (406)
Therapeutic product effect incomplete (400)
Drug ineffective (318)
Sleep disorder due to a general medical condition (318)
Cardiac disorder (311)
Headache (308)
Loss of personal independence in daily activities (301)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
Which MOMETASONE Alternatives Have Lower Bladder transitional cell carcinoma Risk?
MOMETASONE vs MOMETASONE FUROATE
MOMETASONE vs MOMETASONE FUROATE\OLOPATADINE
MOMETASONE vs MONOMETHYL
MOMETASONE vs MONTELUKAST
MOMETASONE vs MONTELUKAST\MONTELUKAST